Kornimate/medical-research-clean huggingface dataset:
home-based asthma support and education for adults

Conditions: Asthma

Summary: this study tests the hypothesis that community health workers providing home visits to provide education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers over the course of one year would reduce asthma morbidity, asthma-related urgent health care use and exposure to indoor asthma triggers among low income adults with not well controlled asthma.

we used a randomized controlled parallel group design to compare the intervention to a usual-care control group. we attempted to evaluate the effectiveness of the intervention in the "real world," rather than its ideal efficacy. the chws used protocols that specified education content, participant skill development and participant and chw actions. the chws modified their approach to meet the priorities of participants using motivational interviewing techniques. they addressed asthma patho-physiology, reliever and controller medication use, self-monitoring, use of an asthma action plan, environmental assessment, trigger avoidance, effective use of the health care system, successful communication with health care providers, and weight control (obesity is associated with increased asthma symptoms). participants also received low-literacy educational materials, in english or spanish. the education concepts and environmental assessment activities were based on our prior healthy homes work modified for adults.

Eligibility criteria:
inclusion criteria: * residence of king county washington * household income below the 250% of the 2007 federal poverty level * had "not well controlled asthma" or "very poorly controlled asthma" exclusion criteria: * speak a language other than english or spanish * no permanent housing

Keywords: asthma
effect of magnetic therapy and moderate aerobic exercise on post thyroidectomy osteoporosis

Conditions: Osteoporosis

Summary: objectives; this study was conducted to investigate the effect of pulsed magnetic therapy and aerobic exercise on post thyroidectomy osteoporosis. methods; forty-five female patients, age ranged from 40 to 50 years old with osteoporotic changes in hip and pelvic region post thyroidectomy, were included in this study. they were selected from endocrinology private clinics. they were assigned randomly into three groups, equal in number. magnetic therapy group (group a); patients received the routine medical treatment (bisphosphonates, calcium, and vitamin d) in addition to pulsed magnetic therapy on the pelvic region for 12 weeks (3 sessions/ week). exercise group(group b); patients received the routine medical treatment in addition to moderate-intensity aerobic exercise for 12 weeks (3 sessions/week). combined magnetic therapy and exercise therapy group (group c): patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks. evaluation of the three groups was performed at baseline and after 12 weeks of treatment by dual energy x-ray absorptiometry (dexa).


Eligibility criteria:
inclusion criteria: * all participants had undergone thyroidectomy since 6 months and had cognitive and educational level enough to understand the requirements of the study exclusion criteria: * all patients with malignancies or receiving radiotherapy or chemotherapy, skin diseases, deep venous thrombosis or venous insufficiency, sensory impairment, renal failure, recent therapy with immunosuppressant or anticonvulsants, psychological problems or alcoholic drinkers were excluded from this study.
explore the optimal surgical timing for lung surgery and mediastinal surgery after covid-19 infection

Conditions: Thoracic Diseases; Thoracic Surgery

Summary: exploring the optimal interval time in patients with the clinical diagnosis of lung cancer or mediastinal tumors indicated for thoracic surgeries after sars-cov-2 infection by comparing 30-day mortality and 30-day morbidity.


Eligibility criteria:
inclusion criteria: 1. the patient has fully understood the nature of this study and voluntarily agreed to participate by signing an informed consent form. 2. participants of any gender between the ages of 18 and 85 are eligible. 3. preoperative imaging evaluation +/- biopsies indicates that the patient has resectable lung cancer or mediastinal tumors without distant metastasis. exclusion criteria: 1. patients who have previously undergone lung surgery; 2. patients previously infected with sars-cov-2 more than 6 months before thoracic surgery; 3. patients who did not receive chest computed tomography (ct) at admission or within 7 days before surgery, or whose chest ct at admission suggests pneumonia or current infection with sars-cov-2 (confirmed by routine laboratory tests as positive nucleic acid in admission or on the day of surgery); 4. the elapsed time from sars-cov-2 diagnosis to surgery is within 4 weeks; 5. local unresectable lesions or distant metastases are found intraoperatively.
a trial of shr-a2102 with other antitumor therapies in advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the study is being conducted to evaluate the safety, tolerability and efficacy of shr-a2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of shr-a2102 for advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. the age of signing the informed consent is 18 -70 years, regardless of gender. 2. at least one measurable lesion according to recist v1.1 criteria. 3. the ecog score is 0 or 1. 4. expected survival ≥12 weeks. 5. good level of organ function. 6. have the ability to give informed consent and to comply with the treatment plan. 7. male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods. exclusion criteria: 1. inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases. 2. spinal cord compression not cured by surgery and/or radiotherapy. 3. subjects with uncontrolled tumor-related pain. 4. received antitumor therapy within 4 weeks before the start of the study. 5. subjects with severe cardiovascular and cerebrovascular disease. 6. history of immunodeficiency, including a positive hiv test.
sentus qp - extended crt evaluation with quadripolar left ventricular leads

Conditions: Heart Failure

Summary: the qp excels study is designed to confirm safety and efficacy of the biotronik sentus otw qp left ventricular leads to satisfy fda requirements for regulatory approval of the leads in the us. the sentus otw qp leads received fda approval on may 4, 2017. long-term safety of the biotronik sentus otw qp left ventricular leads will be confirmed during the ongoing post approval phase (us sites only). a protocol update was implemented on september 6, 2019 to transition the long-term follow up for the ongoing sentus qp study to a new ep passion real-world data methodology.


Eligibility criteria:
inclusion criteria: * standard crt-d indication according to clinical routine * de novo implantation or upgrade from existing icd or pacemaker implant utilizing a biotronik crt-d system with is4 lv port and sentus qp lv lead * patient is able to understand the nature of the clinical investigation and provide written informed consent * patient is able and willing to complete all routine study visits at the investigational site through 5 years of follow-up * patient accepts home monitoring® concept * age ≥ 18 years exclusion criteria: * chronic atrial fibrillation * contraindication to crt-d therapy * currently implanted with an endocardial or epicardial left ventricular lead or had prior attempt to place a left ventricular lead * cardiac surgical procedure, such as coronary artery bypass graft or valve surgery that is planned to occur within 6 months after implant or ablation that is planned to occur within 90 days after implant (ablations planned to occur prior to or at implant are not exclusionary) * expected to receive a heart transplant or ventricular assist device within 6 months * life expectancy less than 12 months * participation in any other investigational cardiac clinical investigation during the course of the study * presence of another life-threatening, underlying illness separate from their cardiac disorder * pregnant or breast-feeding at time of enrollment

Keywords: crt-d therapy quadripolar left ventricular lead
phase 1 study of gsk3228836 pharmacokinetics in participants with hepatic impairment

Conditions: Hepatitis B

Summary: this is a phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of gsk3228836 in participants with child-pugh b (cp-b) cirrhosis (moderate hepatic impairment), child-pugh a (cp-a) cirrhosis (mild hepatic impairment) and participants with normal hepatic function as healthy control.


Eligibility criteria:
inclusion criteria: * body weight \>50 kilogram (kg) and body mass index (bmi) within the range 19 to 40 kilogram per square meters (kg/m2) (inclusive) * capable of giving signed informed consent. * child-pugh b cirrhosis (moderate hepatic impairment; part 1) or child-pugh a cirrhosis (mild hepatic impairment; part 2) or a healthy control participant based on a medical evaluation including medical history, physical examination (pe), laboratory tests. exclusion criteria: * diagnosed or suspected hepatocellular carcinoma. * history of malignancy within the past 5 years except for cancers that are cured by surgical resection (e.g., skin cancer). * history of vasculitis or presence of symptoms and signs of potential vasculitis or history/presence of other diseases that may be associated with vasculitis condition. * unstable cardiac function or high blood pressure that is not controlled (based on the investigator's discretion). * any other medical condition which, in the judgment of the investigator and medical monitor, could jeopardize the integrity of the data derived from that participant or the safety of the participant. * participants who have taken or are currently taking any therapies not allowed by the protocol. * a positive test for human immunodeficiency virus (hiv) antibody. * history of sensitivity to gsk3228836 or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.

Keywords: gsk3228836 hepatitis b child-pugh b (cp-b) cirrhosis child-pugh a (cp-a) cirrhosis pharmacokinetics b-assured
a safety and efficacy study for infliximab (remicade) with methotrexate in patients with early rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the efficacy and safety of infliximab (remicade) in patients with early rheumatoid arthritis.

this is a randomized, multicenter, double-blind, active-treatment-controlled, three-arm, parallel study of chronic treatment with infliximab. this study will determine whether infliximab, at two different doses (3 mg/kg or 6 mg/kg) in combination with methotrexate (mtx), reduces the signs and symptoms (such as joint pain, swelling and stiffness) of rheumatoid arthritis. the study will also compare their effect on slowing down the joint damage associated with rheumatoid arthritis. additional information on the safety of infliximab treatment will be obtained. the study will last for about 1 year. patients will receive methotrexate and total of eight intravenous infusions of the study medication (infliximab or placebo) spaced out over the first year. after the final infusion of study medication, several follow-up visits are to be made. patients will receive methotrexate (start at 7.5mg/wk, increased to 20mg/wk by week8) and intravenous infusions of the study medication (infliximab 3 or 6mg/kg, or placebo) at week 0, 2, and 6, and every 8 weeks thereafter through week 46.

Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis for at least 3 months and less than or equal to 3 years before screening * active disease at the time of screening and pre-infusion of the drug exclusion criteria: * pregnant, nursing, or planning a pregnancy within 18 months of enrollment * incapacitated, largely or wholly bedridden, or confined to a wheelchair, or had little or no ability for self care * rheumatic disease other than rheumatoid arthritis or any current systemic inflammatory condition

Keywords: early rheumatoid arthritis
hanger helmet study

Conditions: Plagiocephaly; Craniosynostosis

Summary: the purpose of this study is to examine a group of patients requiring helmet therapy (either patients with plagiocephaly or post-surgical patients) to compare outcomes of infants treated with the hanger helmet (hanger, inc.) to outcomes of infants treated with the p pod helmet (lorica scientific, llc). currently both helmets are prescribed at cchmc. the investigators' goal is to determine which helmet is more effective in skull remodeling and to standardize the investigators' care for these patient types.

the use of helmet therapy to correct abnormal head shape due to either positional plagiocephaly secondary to pressure on the posterior skull with infant position and furniture use or after minimally invasive surgery for craniosynostosis is currently the treatment of choice at cincinnati children's hospital (cchmc). helmet treatment in children with positional plagiocephaly is initiated for infants between 4 and 9 months of age (at cchmc). helmet treatment for children undergoing surgery for craniosynostosis is initiated following endoscopic cranial vault and stip craniectomy surgery after swelling from the surgery has subsided (generally within two weeks of surgery). treatment with helmet therapy has been shown to improve head shape in both patient diagnoses. there are two types of helmets available to the investigators' patients (hanger helmet and p pod helmet) and to date, no research has evaluated whether one helmet type is more efficient in reshaping the skull than the other type. the current study seeks to fill this gap in the literature by comparing the outcomes for infants treated with a hanger helmet to the outcomes for infants treated with a p pod helmet. the investigators will measure skull symmetry with a 3dmd camera and take routine cross lateral measurements with a caliper designed for this use. infants participating in the study will be randomized using a computerized program, minim.

Eligibility criteria:
inclusion criteria: * diagnosis which requires helmet therapy treatment * under 10 months of age exclusion criteria: * children who do not need helmet therapy

Keywords: helmet hangar p-pod plagiocephaly surgery
therapy with high clopidogrel dose or prasugrel standard dose reduces the platelet reactivity in patients with genotype variation reset gene trial

Conditions: Acute Coronary Syndrome

Summary: dual antiplatelet therapy with aspirin and clopidogrel for at least one year is essential in patients following an acute coronary syndrome (acs) or percutaneous coronary intervention (pci) with drug eluting stent(s. interindividual variability in platelet response to clopidogrel has been reported, with several mechanisms being implicated for high post-clopidogrel treatment pr. high on-treatment platelet reactivity (htpr) is associated with an increased risk of adverse events after pci. studies in patients on chronic clopidogrel treatment are scarce, mainly in diabetic patients where htpr is frequently present and independently predictive of adverse events. optimization of platelet inhibition in patients with htpr by increasing clopidogrel or alternatively, by more potent p2y12 inhibitors is a controversial issue, mostly studied in post pci patients, while no data exist, to the best of the investigators knowledge, in stable patients on chronic clopidogrel treatment. therefore all htpr patients, that will accept to participate, will be enrolled will randomize (day 0) in a 1:1 ratio to either clopidogrel 150 mg a day, or prasugrel 10 mg a day, until day 14 post randomization. a 14 ± 2 day visit will be performed for pr measurement and safety evaluation, with the blood sample being will be obtained 16-18 hours after the last study-drug dose, will follow by crossover directly to the alternate therapy for an additional 14 days without an intervening washout period. at day 28 ± 2 patients will return for the clinical and laboratory assessment as did on day 14 visit.


Eligibility criteria:
inclusion criteria: * patients underwent to pci * lopidogrel resistance after platelet reactivity blood test exclusion criteria: * history of bleeding diathesis * chronic oral anticoagulation treatment * contraindications to antiplatelet therapy * pci or coronary artery bypass grafting (cabg) \<3 months * hemodynamic instability * platelet count \<100,000/μl * hematocrit \<30% * creatinine clearance \<25 ml/min * patients with a history of stroke * contraindication for prasugrel administration * patients weighing \<60 kg * \>75 years of age.

Keywords: antiplatelet effect prasugrel clopidogrel acs
amino acids, serotonin, and body weight regulation

Conditions: Anorexia Nervosa

Summary: this study will assess the behavioral effects of an amino acid mixture thought to influence serotonin function in individuals who have recovered from anorexia nervosa.

anorexia nervosa is a serious psychiatric disorder resulting in psychosocial distress for patients and their families, potentially severe medical consequences, and substantial long-term mortality. a major emphasis in current therapeutic research in anorexia nervosa is exploration of new interventions to stabilize recovery and prevent relapse. although the etiology of anorexia nervosa is unknown, altered regulation of the neurotransmitter serotonin in the central nervous system is thought to contribute to preoccupation with body shape and weight, dysregulated eating patterns, persistent anxiety, and frequent mood fluctuations. the goal of this exploratory project is to assess the behavioral effects of an amino acid mixture thought to influence serotonin function in individuals who have recovered from anorexia nervosa. it is hypothesized that this brief intervention will help diminish residual eating disorder symptoms. all participants in this crossover study will attend eight sessions over a 9-week period. participants will spend approximately 2 weeks in each phase, during which they will receive an amino acid mixture and the control condition.

Eligibility criteria:
inclusion criteria: * history of anorexia nervosa * in normal weight range with resumed menses * no recent bulimic episodes * persistent symptoms of anxiety exclusion criteria: * currently treated with psychotropic medication * diagnosed with major depression * current or recent substance dependence * serious medical illness * pregnant or breastfeeding
dance4healing: explore the benefits of tele-dance in individuals with an implantable cardioverter-defibrillator (icd)

Conditions: ICD; Anxiety; Patient Engagement

Summary: this study is to determine if it is feasible to using a telehealth dance platform with patients that have an implantable cardioverter defibrillator, and will compare the activity engagement, anxiety, and quality of life


Eligibility criteria:
inclusion criteria: 1. patients that have had an icd implanted for at least 1 month 2. patients have access to web-based on-line programs 3. patient can provide cardiac clearance for exercise from their treating physician or they have written stress test results from within the last 6 months indicating no ischemia. 4. patient is 18 years old or greater. exclusion criteria: 1. patient is non-english speaking. 2. patient is assessed as having nyha class iv heart failure. 3. patient had ventricular tachycardia (vt), ventricular fibrillation (vf) or has received "tachy" therapy from their icd within last 4 weeks. 4. patient has had a change in medical arrhythmia management or ablation procedure within the last 4 weeks. 5. any medical issues that compromise walking or dancing, including cardiac, neurological or orthopedic .

Keywords: icd anxiety qol engagement
low-dose chemotherapy under hypoglycaemia for the treatment of relapsed refractory advanced solid tumours

Conditions: Solid Tumors, Adult

Summary: by controlling the patient's blood sugar, small doses of chemotherapy are used in a hypoglycemic state. some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, and produce very strong anticancer effects without the cytotoxic effects of chemotherapy.


Eligibility criteria:
inclusion criteria: 1. male or female aged 18-75 years; 2. asubjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy; 3. subjects have at least one measurable lesion according to response evaluation criteria in solid tumors (recist 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm); 4. ecog score of 0-2, lifespan \> 12 weeks; 5. women of childbearing age who have a negative pregnancy test within 7 days before treatment. female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug; 6. voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up exclusion criteria: 1. the patient is diagnosed with central nervous system leukemia(symptoms, signs, imaging, cerebrospinal fluid); 2. white blood cell count ≥ 50×10\^9/ l or patients with rapid disease progression can't be guaranteed to complete a full treatment cycle; 3. patients with fungal, bacterial, viral or other uncontrollable infections or requiring four-level isolation treatment. 4. hiv, hbv and hcv positive; 5. patients with diseases of the central nervous system or autoimmune central nervous system lesions, including stroke, epilepsy, dementia; 6. patients have myocardial infection, cardiac angiography or stents, active angina or other obvious clinical symptoms, or have cardiopathic asthma or cardiovascular lymphocytic infiltrates，within 12 months; 7. patients are on anticoagulation or have severe coagulopathy (aptt\>70); 8. patients in any condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 2weeks prior to investigational drug administration; 9. patients were infected with covid-19 within 2weeks prior to investigational drug administration; 10. subjects having any serious uncontrolled disease or in other conditions that would preclude them from receiving study treatment and are considered unsuitable for this study in the opinion of the investigator; 11. subjects in other conditions that are considered unsuitable for this study by the investigator.-